183 related articles for article (PubMed ID: 19484128)
1. Proton pump inhibitors exert anti-allergic effects by reducing TCTP secretion.
Choi S; Min HJ; Kim M; Hwang ES; Lee K
PLoS One; 2009 Jun; 4(6):e5732. PubMed ID: 19484128
[TBL] [Abstract][Full Text] [Related]
2. Targeting the translationally controlled tumor protein by a monoclonal antibody improves allergic airway inflammation in mice.
Bae HD; Cho M; Seo H; Lyoo IK; Lee K
Biomed Pharmacother; 2023 Dec; 168():115655. PubMed ID: 37806090
[TBL] [Abstract][Full Text] [Related]
3. Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein.
Pauli-Magnus C; Rekersbrink S; Klotz U; Fromm MF
Naunyn Schmiedebergs Arch Pharmacol; 2001 Dec; 364(6):551-7. PubMed ID: 11770010
[TBL] [Abstract][Full Text] [Related]
4. The basis of differentiation of PPIs.
Sachs G; Shin JM
Drugs Today (Barc); 2004 Mar; 40 Suppl A():9-14. PubMed ID: 15190382
[TBL] [Abstract][Full Text] [Related]
5. Correlation between acid secretion and proton pump activity during inhibition by the proton pump inhibitors omeprazole and pantoprazole.
Nishioka K; Nagao T; Urushidani T
Biochem Pharmacol; 1999 Oct; 58(8):1349-59. PubMed ID: 10487539
[TBL] [Abstract][Full Text] [Related]
6. Flexible loop and helix 2 domains of TCTP are the functional domains of dimerized TCTP.
Lee H; Kim MS; Lee JS; Cho H; Park J; Hae Shin D; Lee K
Sci Rep; 2020 Jan; 10(1):197. PubMed ID: 31932619
[TBL] [Abstract][Full Text] [Related]
7. Differences in binding properties of two proton pump inhibitors on the gastric H+,K+-ATPase in vivo.
Shin JM; Sachs G
Biochem Pharmacol; 2004 Dec; 68(11):2117-27. PubMed ID: 15498502
[TBL] [Abstract][Full Text] [Related]
8. Dimerization of translationally controlled tumor protein is essential for its cytokine-like activity.
Kim M; Min HJ; Won HY; Park H; Lee JC; Park HW; Chung J; Hwang ES; Lee K
PLoS One; 2009 Jul; 4(7):e6464. PubMed ID: 19649253
[TBL] [Abstract][Full Text] [Related]
9. Effects of pantoprazole on xenobiotic metabolizing enzymes in rat liver microsomes: a comparison with other proton pump inhibitors.
Masubuchi N; Hakusui H; Okazaki O
Drug Metab Dispos; 1997 May; 25(5):584-9. PubMed ID: 9152597
[TBL] [Abstract][Full Text] [Related]
10. Effects of pantoprazole, a novel H+/K+-ATPase inhibitor, on duodenal ulcerogenic and healing responses in rats: a comparative study with omeprazole and lansoprazole.
Takeuchi K; Konaka A; Nishijima M; Kato S; Yasuhiro T
J Gastroenterol Hepatol; 1999 Mar; 14(3):251-7. PubMed ID: 10197495
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of omeprazole, lansoprazole, pantoprazole, and rabeprazole in the treatment of acid-related diseases.
Welage LS; Berardi RR
J Am Pharm Assoc (Wash); 2000; 40(1):52-62; quiz 121-3. PubMed ID: 10665250
[TBL] [Abstract][Full Text] [Related]
12. Effect of pantoprazole versus other proton pump inhibitors on 24-hour intragastric pH and basal acid output in Zollinger-Ellison syndrome.
Ramdani A; Mignon M; Samoyeau R
Gastroenterol Clin Biol; 2002 Apr; 26(4):355-9. PubMed ID: 12070410
[TBL] [Abstract][Full Text] [Related]
13. Negative inotropy of the gastric proton pump inhibitor pantoprazole in myocardium from humans and rabbits: evaluation of mechanisms.
Schillinger W; Teucher N; Sossalla S; Kettlewell S; Werner C; Raddatz D; Elgner A; Tenderich G; Pieske B; Ramadori G; Schöndube FA; Kögler H; Kockskämper J; Maier LS; Schwörer H; Smith GL; Hasenfuss G
Circulation; 2007 Jul; 116(1):57-66. PubMed ID: 17576869
[TBL] [Abstract][Full Text] [Related]
14. Metabolic interactions of the proton-pump inhibitors lansoprazole, omeprazole and pantoprazole with other drugs.
Meyer UA
Eur J Gastroenterol Hepatol; 1996 Oct; 8 Suppl 1():S21-5. PubMed ID: 8930576
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms of protection by pantoprazole against NSAID-induced gastric mucosal damage.
Fornai M; Natale G; Colucci R; Tuccori M; Carazzina G; Antonioli L; Baldi S; Lubrano V; Abramo A; Blandizzi C; Del Tacca M
Naunyn Schmiedebergs Arch Pharmacol; 2005 Jul; 372(1):79-87. PubMed ID: 16080005
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and effect on caffeine metabolism of the proton pump inhibitors, omeprazole, lansoprazole, and pantoprazole.
Andersson T; Holmberg J; Röhss K; Walan A
Br J Clin Pharmacol; 1998 Apr; 45(4):369-75. PubMed ID: 9578184
[TBL] [Abstract][Full Text] [Related]
17. Pantoprazole versus omeprazole: influence on meal-stimulated gastric acid secretion.
Dammann HG; Burkhardt F
Eur J Gastroenterol Hepatol; 1999 Nov; 11(11):1277-82. PubMed ID: 10563540
[TBL] [Abstract][Full Text] [Related]
18. Review article: the continuing development of proton pump inhibitors with particular reference to pantoprazole.
Huber R; Kohl B; Sachs G; Senn-Bilfinger J; Simon WA; Sturm E
Aliment Pharmacol Ther; 1995 Aug; 9(4):363-78. PubMed ID: 8527612
[TBL] [Abstract][Full Text] [Related]
19. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities.
Li XQ; Andersson TB; Ahlström M; Weidolf L
Drug Metab Dispos; 2004 Aug; 32(8):821-7. PubMed ID: 15258107
[TBL] [Abstract][Full Text] [Related]
20. Pantoprazole treatment does not invoke anti-inflammatory properties in vivo.
Becker TL; Maróstica M; Ribeiro ML; de Mendonça S; Gambero A; Pedrazzoli J
Int Immunopharmacol; 2004 Aug; 4(8):1051-7. PubMed ID: 15222979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
